Cart
sales@molnova.com
L-701252
CAS No. 151057-13-5
L-701252( L-701,252 )
Catalog No. M27646 CAS No. 151057-13-5
glycine-NMDA site antagonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 64 | In Stock |
|
| 10MG | 85 | In Stock |
|
| 25MG | 136 | In Stock |
|
| 50MG | 183 | In Stock |
|
| 100MG | 275 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 675 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameL-701252
-
NoteResearch use only, not for human use.
-
Brief Descriptionglycine-NMDA site antagonist.
-
Descriptionglycine-NMDA site antagonist(In Vivo):L-701252 (50 mg/kg; i.p.) provides a small non-significant protection.
-
In Vitro——
-
In VivoL-701252 (50 mg/kg; i.p.) provides a small non-significant protection. Animal Model:3-Months Male Mongolian gerbils (60 g)Dosage:50 mg/kg Administration:i.p.Result:Provided a small non-significant protection.
-
SynonymsL-701,252
-
PathwayOthers
-
TargetOther Targets
-
Recptorcholine kinase alpha (ChoKα)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number151057-13-5
-
Formula Weight263.68
-
Molecular FormulaC13H10ClNO3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 10 mg/mL (37.92 mM)
-
SMILESOc1c(C(=O)C2CC2)c(=O)[nH]c2cc(Cl)ccc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Trousil S, et al. The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth. Oncotarget. 2016 Jun 14;7(24):37103-37120.
molnova catalog
related products
-
2-(3,4-Dihydroxyphen...
8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside (Compound 3) is natural product that can be isolated from Bidens bipinnata. 8,3′,4′-Trihydroxyflavone-7-O-β-D-glucopyranoside shows 22% inhibition against α-amylase at 0.556 mg/mL.
-
TG2-IN-3h
TG2-IN-3h is a transglutaminase (TGase) inhibitor used in the study of neurological and immune system disorders.
-
Braylin
Braylin has anti-inflammatory, antinociceptive and immunomodulatory effects, which possibly act through the glucocorticoid receptor activation and by inhibition of the transcriptional activity of NF-κB.
